 |
PDBsum entry 1idb
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
|
|
|
|
|
|
|
Hydrolase/hydrolase inhibitor
|
PDB id
|
|
|
|
1idb
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
Contents |
 |
|
|
|
|
|
|
|
|
|
|
|
* Residue conservation analysis
|
|
|
|
 |
|
|
 |
 |
 |
 |
Enzyme class 1:
|
 |
E.C.2.7.7.-
- ?????
|
|
 |
 |
 |
 |
 |
Enzyme class 2:
|
 |
E.C.2.7.7.49
- RNA-directed Dna polymerase.
|
|
 |
 |
 |
 |
 |
Reaction:
|
 |
DNA(n) + a 2'-deoxyribonucleoside 5'-triphosphate = DNA(n+1) + diphosphate
|
 |
 |
 |
 |
 |
DNA(n)
|
+
|
2'-deoxyribonucleoside 5'-triphosphate
|
=
|
DNA(n+1)
|
+
|
diphosphate
|
|
 |
 |
 |
 |
 |
 |
 |
 |
Enzyme class 3:
|
 |
E.C.2.7.7.7
- DNA-directed Dna polymerase.
|
|
 |
 |
 |
 |
 |
Reaction:
|
 |
DNA(n) + a 2'-deoxyribonucleoside 5'-triphosphate = DNA(n+1) + diphosphate
|
 |
 |
 |
 |
 |
DNA(n)
|
+
|
2'-deoxyribonucleoside 5'-triphosphate
|
=
|
DNA(n+1)
|
+
|
diphosphate
|
|
 |
 |
 |
 |
 |
 |
 |
 |
Enzyme class 4:
|
 |
E.C.3.1.-.-
|
|
 |
 |
 |
 |
 |
Enzyme class 5:
|
 |
E.C.3.1.13.2
- exoribonuclease H.
|
|
 |
 |
 |
 |
 |
Reaction:
|
 |
Exonucleolytic cleavage to 5'-phosphomonoester oligonucleotides in both 5'- to 3'- and 3'- to 5'-directions.
|
 |
 |
 |
 |
 |
Enzyme class 6:
|
 |
E.C.3.1.26.13
- retroviral ribonuclease H.
|
|
 |
 |
 |
 |
 |
Enzyme class 7:
|
 |
E.C.3.4.23.47
- HIV-2 retropepsin.
|
|
 |
 |
 |
 |
 |
 |
 |
|
Note, where more than one E.C. class is given (as above), each may
correspond to a different protein domain or, in the case of polyprotein
precursors, to a different mature protein.
|
|
 |
|
Molecule diagrams generated from .mol files obtained from the
KEGG ftp site
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
| |
|
|
| |
|
DOI no:
|
Structure
3:33-40
(1995)
|
|
PubMed id:
|
|
|
|
|
| |
|
Crystal structures of HIV-2 protease in complex with inhibitors containing the hydroxyethylamine dipeptide isostere.
|
|
L.Tong,
S.Pav,
S.Mui,
D.Lamarre,
C.Yoakim,
P.Beaulieu,
P.C.Anderson.
|
|
|
|
| |
ABSTRACT
|
|
|
| |
|
BACKGROUND: The HIV protease is essential for the life cycle of the virus and is
an important target for the development of therapeutic treatments against AIDS.
The structures of HIV protease in complex with different inhibitors have helped
in understanding the interactions between inhibitors and the protease and in the
design and optimization of HIV protease inhibitors. RESULTS: We report here
crystal structures at up to 1.7 A resolution of the homodimeric HIV-2 protease
in complex with seven inhibitors containing the hydroxyethylamine dipeptide
isostere. A novel dimethylphenoxyacetyl group that is present in some of these
inhibitors is inserted between residues 48' and 49' in the flap of the protease
and residues 29' and 30' (where a prime indicates a residue in the second
monomer), which undergo a conformational change to accommodate the phenyl ring
of the inhibitor. CONCLUSIONS: This study shows that besides the residues in the
flap and residues 79-81 in the S1 substrate-binding pocket which undergo
conformational changes upon inhibitor binding, residues 29 and 30 can also adapt
their conformation to fit certain inhibitors. Conformational flexibility of the
HIV protease plays an important role in inhibitor binding.
|
|
|
|
|
| |
Selected figure(s)
|
|
|
| |
 |
 |
|
 |
|
 |
Figure 5.
Figure 5. The binding modes of the inhibitors. (a) Overlap of
the bound conformation of the long inhibitors 1 (red), 2 (cyan)
and 3 (black). (b) Overlap of the bound conformation of the
short inhibitors 4 (black), 5 (cyan), 6 (pink) and 7 (green). (c
) Overlap of the bound conformation of the long inhibitor 1
(red) and the short inhibitor 7 (green) . Figure 5. The
binding modes of the inhibitors. (a) Overlap of the bound
conformation of the long inhibitors 1 (red), 2 (cyan) and 3
(black). (b) Overlap of the bound conformation of the short
inhibitors 4 (black), 5 (cyan), 6 (pink) and 7 (green). (c )
Overlap of the bound conformation of the long inhibitor 1 (red)
and the short inhibitor 7 (green) .
|
 |
Figure 6.
Figure 6. (a) Hydrogen-bonding interactions between inhibitor 1
and the protease. (b) The interactions between the hydroxyl of
the isostere and the catalytic aspartic acid residues .
Figure 6. (a) Hydrogen-bonding interactions between inhibitor 1
and the protease. (b) The interactions between the hydroxyl of
the isostere and the catalytic aspartic acid residues .
|
 |
|
|
|
| |
The above figures are
reprinted
by permission from Cell Press:
Structure
(1995,
3,
33-40)
copyright 1995.
|
|
| |
Figures were
selected
by an automated process.
|
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Literature references that cite this PDB file's key reference
|
|
 |
| |
PubMed id
|
 |
Reference
|
 |
|
|
|
 |
J.M.Louis,
R.Ishima,
A.Aniana,
and
J.M.Sayer
(2009).
Revealing the dimer dissociation and existence of a folded monomer of the mature HIV-2 protease.
|
| |
Protein Sci,
18,
2442-2453.
|
 |
|
|
|
|
 |
A.Y.Kovalevsky,
J.M.Louis,
A.Aniana,
A.K.Ghosh,
and
I.T.Weber
(2008).
Structural evidence for effectiveness of darunavir and two related antiviral inhibitors against HIV-2 protease.
|
| |
J Mol Biol,
384,
178-192.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
Y.Zhao,
and
M.F.Sanner
(2007).
FLIPDock: docking flexible ligands into flexible receptors.
|
| |
Proteins,
68,
726-737.
|
 |
|
|
|
|
 |
H.B.Thorsteinsdottir,
T.Schwede,
V.Zoete,
and
M.Meuwly
(2006).
How inaccuracies in protein structure models affect estimates of protein-ligand interactions: computational analysis of HIV-I protease inhibitor binding.
|
| |
Proteins,
65,
407-423.
|
 |
|
|
|
|
 |
P.Bagossi,
T.Sperka,
A.Fehér,
J.Kádas,
G.Zahuczky,
G.Miklóssy,
P.Boross,
and
J.Tözsér
(2005).
Amino acid preferences for a critical substrate binding subsite of retroviral proteases in type 1 cleavage sites.
|
| |
J Virol,
79,
4213-4218.
|
 |
|
|
|
|
 |
H.M.Abdel-Rahman,
N.A.el-Koussi,
G.S.Alkaramany,
A.F.Youssef,
and
Y.Kiso
(2004).
A novel dipeptide-based HIV protease inhibitor containing allophenylnorstatine.
|
| |
Arch Pharm (Weinheim),
337,
587-598.
|
 |
|
|
|
|
 |
S.J.Teague
(2003).
Implications of protein flexibility for drug discovery.
|
| |
Nat Rev Drug Discov,
2,
527-541.
|
 |
|
|
|
|
 |
D.J.Diller,
and
K.M.Merz
(2001).
High throughput docking for library design and library prioritization.
|
| |
Proteins,
43,
113-124.
|
 |
|
|
|
|
 |
C.M.Stultz,
and
M.Karplus
(1999).
MCSS functionality maps for a flexible protein.
|
| |
Proteins,
37,
512-529.
|
 |
|
|
|
|
 |
A.Wlodawer,
and
J.Vondrasek
(1998).
Inhibitors of HIV-1 protease: a major success of structure-assisted drug design.
|
| |
Annu Rev Biophys Biomol Struct,
27,
249-284.
|
 |
|
|
|
|
 |
H.L.Sham,
D.J.Kempf,
A.Molla,
K.C.Marsh,
G.N.Kumar,
C.M.Chen,
W.Kati,
K.Stewart,
R.Lal,
A.Hsu,
D.Betebenner,
M.Korneyeva,
S.Vasavanonda,
E.McDonald,
A.Saldivar,
N.Wideburg,
X.Chen,
P.Niu,
C.Park,
V.Jayanti,
B.Grabowski,
G.R.Granneman,
E.Sun,
A.J.Japour,
J.M.Leonard,
J.J.Plattner,
and
D.W.Norbeck
(1998).
ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease.
|
| |
Antimicrob Agents Chemother,
42,
3218-3224.
|
 |
|
|
|
|
 |
D.Lamarre,
G.Croteau,
E.Wardrop,
L.Bourgon,
D.Thibeault,
C.Clouette,
M.Vaillancourt,
E.Cohen,
C.Pargellis,
C.Yoakim,
and
P.C.Anderson
(1997).
Antiviral properties of palinavir, a potent inhibitor of the human immunodeficiency virus type 1 protease.
|
| |
Antimicrob Agents Chemother,
41,
965-971.
|
 |
|
|
|
|
 |
G.Croteau,
L.Doyon,
D.Thibeault,
G.McKercher,
L.Pilote,
and
D.Lamarre
(1997).
Impaired fitness of human immunodeficiency virus type 1 variants with high-level resistance to protease inhibitors.
|
| |
J Virol,
71,
1089-1096.
|
 |
|
|
|
|
 |
G.Lange-Savage,
H.Berchtold,
A.Liesum,
K.H.Budt,
A.Peyman,
J.Knolle,
J.Sedlacek,
M.Fabry,
and
R.Hilgenfeld
(1997).
Structure of HOE/BAY 793 complexed to human immunodeficiency virus (HIV-1) protease in two different crystal forms--structure/function relationship and influence of crystal packing.
|
| |
Eur J Biochem,
248,
313-322.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
L.Doyon,
G.Croteau,
D.Thibeault,
F.Poulin,
L.Pilote,
and
D.Lamarre
(1996).
Second locus involved in human immunodeficiency virus type 1 resistance to protease inhibitors.
|
| |
J Virol,
70,
3763-3769.
|
 |
|
 |
 |
|
The most recent references are shown first.
Citation data come partly from CiteXplore and partly
from an automated harvesting procedure. Note that this is likely to be
only a partial list as not all journals are covered by
either method. However, we are continually building up the citation data
so more and more references will be included with time.
Where a reference describes a PDB structure, the PDB
codes are
shown on the right.
|
');
}
}
 |